SGLT2 Inhibitor- Induced Euglycaemic Diabetic Ketoacidosis May be due to Abrupt, Severe and Transient Impaired Glucose Sensing in Susceptible Individuals with a Hitherto Unrecognised Beta Cell SGLT Variant

Euglycaemic diabetic ketoacidosis (EDKA) is a rare complication of treatment with SGLT2 inhibitors in patients with type 2 diabetes. Uncertainty remains about its precise mechanistic basis, but the physiological derangement is acute and profound, yet reversible with cessation of the drug. It is reminiscent of other “non type 1” presentations with DKA such as ketosis prone diabetes, except that glucose levels are usually normal. Impaired beta cell glucose sensing that mimicked a state of hypoglycaemia could theoretically lead to abrupt and transient cessation of insulin secretion.

Source: Medical Hypotheses - February 23, 2018 Category: Biomedical Science Authors: F.M. Finucane Source Type: research